Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-024684

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — See Remarks · Director
Period of report
Oct 23, 2017
Accepted (ET)
Oct 25, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF2,F3Oct 23, 2017S75,468$33.2309D339,840D
Common Stock, $0.0001 par valueF4,F3Oct 23, 2017S17,472$34.1509D322,368D
Common Stock, $0.0001 par valueF5,F3Oct 23, 2017S6,960$35.3921D315,408D
Common Stock, $0.0001 par valueF3Oct 23, 2017S100$36.55D315,308D
Common Stock, $0.0001 par valueF6holding———41,075IBy Child's Trust 1
Common Stock, $0.0001 par valueF7holding———20,656IBy Family Trust
Common Stock, $0.0001 par valueF8holding———41,075IBy Child's Trust 2
Common Stock, $0.0001 par valueF9holding———14,447IBy GRAT 2
Common Stock, $0.0001 par valueF10holding———14,447IBy Wife's GRAT 2

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

President and Chief Executive Officer